Variant Summary
- Also known as
- VAL600
- HGVS
- —
- Variant Type(s)
- protein_altering_variant
- Evidence Items
- 24
Evidence Level Distribution
Level A: 4Level B: 18Level C: 2
Evidence Items
Showing CIViC evidence rows where gene = BRAF and variant = V600.
| Level | Type | Direction | Significance | Disease | Drugs | Rating |
|---|---|---|---|---|---|---|
| A | Predictive | Supports | Sensitivity/Response | Skin Melanoma | Trametinib,Dabrafenib | 5 |
| A | Predictive | Supports | Sensitivity/Response | Melanoma | Vemurafenib,Cobimetinib | 5 |
| B | Predictive | Supports | Sensitivity/Response | Melanoma | Trametinib,Dabrafenib | 5 |
| B | Predictive | Supports | Sensitivity/Response | Melanoma | Trametinib,Dabrafenib | 5 |
| A | Predictive | Supports | Sensitivity/Response | Melanoma | Encorafenib,Binimetinib | 5 |
| A | Predictive | Supports | Sensitivity/Response | Melanoma | Atezolizumab,Vemurafenib,Cobimetinib | 4 |
| B | Predictive | Supports | Sensitivity/Response | Melanoma | Dabrafenib | 4 |
| B | Predictive | Supports | Sensitivity/Response | Melanoma | Cobimetinib,Vemurafenib | 4 |
| B | Diagnostic | Supports | Positive | Melanoma | 4 | |
| B | Predictive | Supports | Sensitivity/Response | Cholangiocarcinoma | Vemurafenib | 4 |
| B | Predictive | Supports | Sensitivity/Response | Colorectal Cancer | Encorafenib,Cetuximab | 4 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Vemurafenib | 3 |
| B | Predictive | Supports | Sensitivity/Response | Langerhans-cell Histiocytosis | Vemurafenib | 3 |
| B | Predictive | Supports | Resistance | Colorectal Cancer | Vemurafenib | 3 |
| B | Predictive | Supports | Sensitivity/Response | Melanoma | Trametinib | 3 |
| B | Predictive | Supports | Sensitivity/Response | Colorectal Cancer | Cetuximab,Alpelisib,Encorafenib | 3 |
| B | Predictive | Supports | Sensitivity/Response | Melanoma | Vemurafenib,Cobimetinib | 3 |
| B | Predictive | Supports | Sensitivity/Response | Colorectal Cancer | Vemurafenib,Cetuximab,Irinotecan | 3 |
| B | Predictive | Supports | Resistance | Colorectal Cancer | Panitumumab | 3 |
| B | Predictive | Supports | Sensitivity/Response | Melanoma | Trametinib,Dabrafenib | 3 |
| C | Predictive | Supports | Resistance | Melanoma | Refametinib | 2 |
| C | Predictive | Supports | Sensitivity/Response | Histiocytic Sarcoma | Dabrafenib/Trametinib Regimen | 2 |
| B | Predictive | Supports | Sensitivity/Response | Colorectal Cancer | Trametinib,Dabrafenib | 2 |
| B | Predictive | Does Not Support | Sensitivity/Response | Colorectal Cancer | Cetuximab,Vemurafenib | 2 |